Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non–small cell lung cancer

JAMA Oncology

Volumn 3, Issue 11, 2017, Pages 1529-1537

  Li, Bailiang ^a   Cui, Yi ^b   Diehn, Maximilian ^a   Li, Ruijiang ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOKKAIDO UNIVERSITY   (Japan)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BIOLOGICAL FUNCTIONS; CANCER ADJUVANT THERAPY; CANCER IMMUNOLOGY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CELL DEATH; CHEMOTAXIS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FROZEN SECTION; GENE CONSTRUCT; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIVIDUALIZED IMMUNE PROGNOSTIC SIGNATURE; LOW RISK PATIENT; LUNG ADENOCARCINOMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; NEUTROPHIL CHEMOTAXIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; VALIDATION STUDY; ADENOCARCINOMA; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LUNG RESECTION; LUNG TUMOR; MIDDLE AGED; MORTALITY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; VERY ELDERLY; YOUNG ADULT;

TRANSCRIPTOME; TUMOR MARKER;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DATABASES, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSCRIPTOME; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 85036504188     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.1609     Document Type: Article

References (77)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
2. Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer. 2016;16(8):525-537.
3. Pignon J-P, Tribodet H, Scagliotti GV, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21): 3552-3559.
4. Sangha R, Price J, Butts CA. Adjuvant therapy in non–small cell lung cancer: current and future directions. Oncologist. 2010;15(8):862-872.
5. Strauss GM, Herndon JE II, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non–small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study groups. J Clin Oncol. 2008;26(31):5043-5051.
6. Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non–small-cell lung cancer: development and international validation studies. Lancet. 2012;379(9818):823-832.
7. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8(8):816-824.
8. Shedden K, Taylor JM, Enkemann SA, et al; Director’s Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008;14(8):822-827.
9. Wistuba II, Behrens C, Lombardi F, et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res. 2013;19(22): 6261-6271.
10. Chen H-Y, Yu S-L, Chen C-H, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356(1):11-20.
11. Subramanian J, Simon R. Gene expression–based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst. 2010;102(7):464-474.
12. Xie Y, Minna JD. A lung cancer molecular prognostic test ready for prime time. Lancet. 2012; 379(9818):785-787.
13. Guo NL, Wan Y-W, Tosun K, et al. Confirmation of gene expression–based prediction of survival in non–small cell lung cancer. Clin Cancer Res. 2008;14 (24):8213-8220.
14. Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet. 2010;11 (10):733-739.
15. Popovici V, Budinska E, Tejpar S, et al. Identification of a poor-prognosis BRAF-mutant–like population of patients with colon cancer. J Clin Oncol. 2012;30(12):1288-1295.
16. Zak DE, Penn-Nicholson A, Scriba TJ, et al; ACS and GC6-74 cohort study groups. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016;387 (10035):2312-2322.
17. Heinäniemi M, Nykter M, Kramer R, et al. Gene-pair expression signatures reveal lineage control. Nat Methods. 2013;10(6):577-583.
18. Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013;25(2):261-267.
19. Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015; 21(8):938-945.
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
21. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480 (7378):480-489.
22. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006; 90:51-81.
23. Gentles AJ, Bratman SV, Lee LJ, et al. Integrating tumor and stromal gene expression signatures with clinical indices for survival stratification of early-stage non–small cell lung cancer. J Natl Cancer Inst. 2015;107(10):djv211.
24. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26): 2443-2454.
25. Garon E, Gandhi L, Rizvi N, et al. LBA43: antitumor activity of pembrolizumab (PEMBRO; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non–small cell lung carcinoma (NSCLC). Ann Oncol. 2014;25(suppl 4): 1-41.
26. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964.
27. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund L-T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non–small cell lung cancer. Clin Cancer Res. 2008;14 (16):5220-5227.
28. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373-5380.
29. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6): 610-618.
30. Galon J, Pagès F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10(1):205.
31. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782-795.
32. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1-2):48-61.
33. Angelova M, Charoentong P, Hackl H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16(1):64.
34. Suzuki K, Kachala SS, Kadota K, et al. Prognostic immune markers in non–small cell lung cancer [published correction appears in Nature. 2014;514(7521):262]. Clin Cancer Res. 2011;17(16): 5247-5256.
35. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-550.
36. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers [published correction appears in Nature. 2012;491(7423):288]. Nature. 2012;489(7417):519-525.
37. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59-73.
38. Rousseaux S, Debernardi A, Jacquiau B, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013;5(186):186ra66.
39. Okayama H, Kohno T, Ishii Y, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2012;72(1):100-111.
40. Sato M, Larsen JE, Lee W, et al. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res. 2013;11(6):638-650.
41. Der SD, Sykes J, Pintilie M, et al. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thorac Oncol. 2014;9(1):59-64.
42. Tomida S, Takeuchi T, Shimada Y, et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol. 2009;27(17):2793-2799.
43. Wilkerson MD, Yin X, Walter V, et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One. 2012;7(5):e36530.
44. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98(24):13790-13795.
45. Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile–defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006;24 (11):1679-1688.
46. Tang H, Xiao G, Behrens C, et al. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non–small cell lung cancer patients. Clin Cancer Res. 2013;19(6):1577-1586.
47. Hou J, Aerts J, den Hamer B, et al. Gene expression-based classification of non–small cell lung carcinomas and survival prediction. PLoS One. 2010;5(4):e10312.
48. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439(7074):353-357.
49. Botling J, Edlund K, Lohr M, et al. Biomarker discovery in non–small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 2013;19(1): 194-204.
50. Kuner R, Muley T, Meister M, et al. Global gene expression analysis reveals specific patterns of cell junctions in non–small cell lung cancer subtypes. Lung Cancer. 2009;63(1):32-38.
51. Zhu CQ, Ding K, Strumpf D, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non–small-cell lung cancer. J Clin Oncol. 2010;28(29):4417-4424.
52. Xie Y, Xiao G, Coombes KR, et al. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non–small-cell lung cancer patients. Clin Cancer Res. 2011;17(17):5705-5714.
53. Bhattacharya S, Andorf S, Gomes L, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014;58(2-3): 234-239.
54. Kim S, Lin CW, Tseng GC. MetaKTSP: a meta-analytic top scoring pair method for robust cross-study validation of omics prediction analysis. Bioinformatics. 2016;32(13):1966-1973.
55. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox’s proportional hazards model via coordinate descent. J Stat Softw. 2011;39 (5):1-13.
56. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56 (2):337-344.
57. Akritas MG. Nearest neighbor estimation of a bivariate distribution under random censoring. Ann Stat. 1994;22(3):1299-1327.
58. Cheng WY, Ou Yang TH, Anastassiou D. Development of a prognostic model for breast cancer survival in an open challenge environment. Sci Transl Med. 2013;5(181):181ra50.
59. Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
60. Cooper LA, Kong J, Gutman DA, Dunn WD, Nalisnik M, Brat DJ. Novel genotype-phenotype associations in human cancers enabled by advanced molecular platforms and computational analysis of whole slide images. Lab Invest. 2015;95 (4):366-376.
61. Eng KH, Schiller E, Morrell K. On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve. Oncotarget. 2015;6(34):36308-36318.
62. Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32 (22):2380-2385.
63. Kang L, Chen W, Petrick NA, Gallas BD. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med. 2015;34(4): 685-703.
64. Zheng Y, Bueno R. Commercially available prognostic molecular models in early-stage lung cancer: a review of the Pervenio Lung RS and Myriad myPlan Lung Cancer tests. Expert Rev Mol Diagn. 2015;15(5):589-596.
65. Tan AC, Naiman DQ, Xu L, Winslow RL, Geman D. Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics. 2005;21(20):3896-3904.
66. Eddy JA, Sung J, Geman D, Price ND. Relative expression analysis for molecular cancer diagnosis and prognosis. Technol Cancer Res Treat. 2010;9(2): 149-159.
67. Suzuki K, Kadota K, Sima CS, et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2013;31(4):490-498.
68. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5):1175-1183.
69. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013; 14(6):e218-e228.
70. Cvetanovic M, Ucker DS. Innate immune discrimination of apoptotic cells: repression of proinflammatory macrophage transcription is coupled directly to specific recognition. J Immunol. 2004;172(2):880-889.
71. Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta. 2006;1757(9-10):1371-1387.
72. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol. 2013;23(3):200-207.
73. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 2009;27(28):4709-4717.
74. Fossati G, Ricevuti G, Edwards SW, Walker C, Dalton A, Rossi ML. Neutrophil infiltration into human gliomas. Acta Neuropathol. 1999;98(4): 349-354.
75. Jensen TO, Schmidt H, Møller HJ, et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer. 2012;118(9):2476-2485.
76. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-892.
77. Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014;346(6206):256-259.